TY - JOUR T1 - Novel 5-Hydroxymethylcytosine Markers for Pancreatic Cancer JF - bioRxiv DO - 10.1101/425983 SP - 425983 AU - Chang Zeng AU - Zhou Zhang AU - Jun Wang AU - Brian C-H. Chiu AU - Lifang Hou AU - Wei Zhang Y1 - 2018/01/01 UR - http://biorxiv.org/content/early/2018/09/25/425983.abstract N2 - OBJECTIVES Robust biomarkers for pancreatic cancer (PaC) early detection/prognosis are critical for improved patient survival. Our goal was to explore the biomarker potential of 5-hydroxymethylcytosines (5hmC), an epigenetic marker with a distinct role in cancer pathobiology, yet under-investigated due largely to technical constraints.METHODS We used the TAB-Array assay, a state-of-the-art technology to directly profile 5hmC at single base resolution with the Illumina EPIC array (>850,000 CpG sites) in 17 pairs of tumor/adjacent tissue samples from US patients.RESULTS We demonstrated distinctive distributions of 5hmC in tissues, and substantial differences between tumor and adjacent tissues, suggesting their diagnostic/prognostic value of for PaC.CONCLUSION This study established the potential of 5hmC as a novel epigenetic biomarker for PaC. ER -